Bessen Laura 4

What Happened

• Laura Bessen, a member of the board of C4 Therapeutics (CCCC), received an award of 62,000 derivative securities on June 24, 2026. The Form 4 reports an acquisition price of $0.00, indicating a grant (option/award) rather than a cash purchase or sale. This was a grant of options/derivative rights—not an exercise or sale—and no shares were sold.

Key Details

• Transaction date: 2026-06-24; filing date: 2026-06-26 (filed within the typical 2-business-day Form 4 window).
• Reported acquisition: 62,000 derivative securities at $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option vests and becomes exercisable in full on the earlier of (i) June 24, 2027 or (ii) the next annual meeting of the issuer’s stockholders, subject to Bessen’s continued board service on that date.
• Filing timeliness: Filed two days after the transaction — appears timely.

Context

• This filing reflects a grant of options/derivative awards, not an exercise or immediate sale; there is no indication shares were sold or that cashless exercise occurred. Exercise price and other plan terms (beyond the vesting trigger above) are not disclosed in the Form 4. Option grants to directors are common as compensation for board service and do not by themselves indicate a change in insider sentiment.